Table 1.

IRF-1, IRF-2, and PD-L1 mRNA in relationship with clinical characteristics of 31 HCC patients included in this study

Variable		IRF-1		IRF-2		PD-L1
	N	Mean ± SEM	p	Mean ± SEM	p	Mean ± SEM	p
Age
≤ 71	17	1.48 ± 0.41	0.106	1.52 ± 0.31	0.105	0.59 ± 0.16	0.329
> 71	14	0.67 ± 0.14		0.90 ± 0.15		0.40 ± 0.07
Sex
Male	23	1.23 ± 0.32	0.403	1.32 ± 0.24	0.481	0.52 ± 0.13	0.702
Female	8	0.76 ± 0.24		1.01 ± 0.23		0.44 ± 0.10
HBs Ag
+	4	0.70 ± 0.33	0.531	1.42 ± 0.53	0.719	0.61 ± 0.35	0.667
−	27	1.17 ± 0.27		1.21 ± 0.20		0.48 ± 0.10
HCV Ab
+	7	1.45 ± 0.49	0.462	1.06 ± 0.13	0.617	0.50 ± 0.25	0.9886
−	24	1.01 ± 0.28		1.29 ± 0.24		0.50 ± 0.10
Differentiation
Well	6	2.31 ± 0.95	0.037*	1.91 ± 0.83	0.218	0.76 ± 0.31	0.269
Moderate	22	0.84 ± 0.18		1.09 ± 0.13		0.46 ± 0.10
Poor	3	0.55 ± 0.03		1.07 ± 0.13		0.18 ± 0.07
TNM stage
I	8	2.49 ± 0.72	0.004**	1.73 ± 0.62	0.514	0.75 ± 0.21	0.159
II	13	0.54 ± 0.10		1.10 ± 0.18		0.38 ± 0.12
IIIA	6	0.58 ± 0.23		1.01 ± 0.30		0.37 ± 0.11
IIIB	4	1.01 ± 0.30		1.07 ± 0.27		0.22 ± 0.07

Bold indicates *p < 0.05, **p < 0.01

HBs Ag, hepatitis; B, surface antigen; HCV Ab, hepatitis C virus antibody; TNM, Tumor Node Metastasis